| 2026-10-15 | Results date moved lead | semaglutide | A Study of BGM0504 in Participants With Type 2 DiabetesNCT06716216 · BrightGene Bio-Medical Technology Co., Ltd. | 2026-03-20 → 2026-11-14 8 mo later | P3 |
| 2026-10-15 | Status changed | semaglutide | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Not yet recruiting → Recruiting | P3 |
| 2026-10-15 | Status changed | semaglutide | A Study of BGM0504 in Participants With Type 2 DiabetesNCT06716216 · BrightGene Bio-Medical Technology Co., Ltd. | Recruiting → Active, not recruiting | P3 |
| 2026-10-15 | New trial registered | tirzepatide | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study | Not yet recruiting, n=30 | P2 |
| 2026-10-14 | Status changed | semaglutide | Semaglutide vs Sitagliptin | Enrolling by invitation → Active, not recruiting | P4 |
| 2026-10-14 | New trial registered | semaglutide | FutureShape Family | Not yet recruiting, n=400 | P4 |
| 2026-10-14 | Status changed | aleniglipron | Aleniglipron Phase 2 Body Composition StudyNCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Active, not recruiting → Completed | P2 |
| 2026-10-14 | Results date moved | aleniglipron | Aleniglipron Phase 2 Body Composition StudyNCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2026-08 → 2026-09-09 1 mo later | P2 |
| 2026-10-13 | Results date moved lead | semaglutide | A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · BrightGene Bio-Medical Technology Co., Ltd. | 2026-07-31 → 2027-04-30 9 mo later | P3 |
| 2026-10-13 | Enrollment changed | semaglutide | A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · BrightGene Bio-Medical Technology Co., Ltd. | 477 → 152 participants | P3 |
| 2026-10-13 | Results date moved | semaglutide | Semaglutide for Helping Opioid Recovery | 2026-08-31 → 2027-09-01 13 mo later | P2 |
| 2026-10-13 | Status changed | ecnoglutide | A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Active, not recruiting → Terminated | P2 |
| 2026-10-13 | Status changed | semaglutide | A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · BrightGene Bio-Medical Technology Co., Ltd. | Recruiting → Active, not recruiting | P3 |
| 2026-10-13 | New trial registered | semaglutide | ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging | Completed, n=31 | P2 |
| 2026-10-13 | New trial registered | semaglutide | A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum | Recruiting, n=96 | P4 |
| 2026-10-13 | Status changed | semaglutide | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Not yet recruiting → Enrolling by invitation | P4 |
| 2026-10-13 | Status changed | tirzepatide | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Not yet recruiting → Recruiting | P3 |
| 2026-10-13 | Status changed | tirzepatide | A Study of BGM0504 in Participants With ObesityNCT06911203 · BrightGene Bio-Medical Technology Co., Ltd. | Recruiting → Completed | P2 |
| 2026-10-13 | Results date moved | tirzepatide | A Study of BGM0504 in Participants With ObesityNCT06911203 · BrightGene Bio-Medical Technology Co., Ltd. | 2026-01-11 → 2026-01-14 | P2 |
| 2026-10-13 | Enrollment changed | tirzepatide | A Study of BGM0504 in Participants With ObesityNCT06911203 · BrightGene Bio-Medical Technology Co., Ltd. | 90 → 96 participants | P2 |
| 2026-10-13 | Status changed | tirzepatide | Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) | Recruiting → Active, not recruiting | P4 |
| 2026-10-13 | Status changed | mazdutide | Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · China National Center for Cardiovascular Diseases | Not yet recruiting → Recruiting | P4 |
| 2026-10-13 | Results date moved | ecnoglutide | A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | 2026-11-30 → 2026-09-11 2 mo earlier | P2 |
| 2026-10-13 | Enrollment changed | ecnoglutide | A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | 120 → 8 participants | P2 |
| 2026-10-13 | New trial registered | maridebart cafraglutide | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Not yet recruiting, n=230 | P3 |
| 2026-10-09 | New trial registered | VK2735 | Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) | Not yet recruiting, n=560 | P3 |
| 2026-10-09 | New trial registered | VK2735 | Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) | Not yet recruiting, n=560 | P3 |
| 2026-10-09 | New trial registered | exenatide | · AMNEAL | | |
| 2026-10-09 | New trial registered | exenatide | · AMNEAL | | |
| 2026-10-09 | New trial registered | exenatide | · AMNEAL | | |
| 2026-10-08 | New trial registered | semaglutide | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Not yet recruiting, n=1,300 | P3 |
| 2026-10-07 | Status changed | semaglutide | Semaglutide in Women With Polycystic Ovary Syndrome and ObesityNCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting → Completed | P2/P3 |
| 2026-10-07 | Enrollment changed | semaglutide | Semaglutide in Women With Polycystic Ovary Syndrome and ObesityNCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 30 → 31 participants | P2/P3 |
| 2026-10-07 | Enrollment changed | semaglutide | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | 210 → 212 participants | P3 |
| 2026-10-07 | Status changed | petrelintide | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease | Not yet recruiting → Recruiting | P3 |
| 2026-10-07 | Status changed | petrelintide | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Not yet recruiting → Recruiting | P3 |
| 2026-10-07 | Status changed | petrelintide | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Not yet recruiting → Recruiting | P3 |
| 2026-10-06 | Status changed | semaglutide | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Recruiting → Active, not recruiting | P3 |
| 2026-10-06 | Enrollment changed | semaglutide | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | 1,200 → 1,270 participants | P3 |
| 2026-10-06 | Results date moved | maridebart cafraglutide | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-09-03 → 2027-08-20 1 mo earlier | P3 |
| 2026-10-05 | New trial registered | semaglutide | The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | Recruiting, n=2,000 | P3 |
| 2026-10-05 | Results date moved | semaglutide | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | 2027-02 → 2029-02 24 mo later | P2 |
| 2026-10-05 | New trial registered | semaglutide | Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNCT07859189 · General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting, n=100 | P4 |
| 2026-10-05 | New trial registered | semaglutide | Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176 · General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting, n=100 | P4 |
| 2026-10-05 | New trial registered | semaglutide | Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNCT07859137 · General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting, n=100 | P4 |
| 2026-10-05 | New trial registered | semaglutide | Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163 · General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting, n=100 | P4 |
| 2026-10-05 | New trial registered | semaglutide | Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150 · General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting, n=104 | P4 |
| 2026-10-05 | New trial registered | semaglutide | Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access | Not yet recruiting, n=880 | P4 |
| 2026-10-05 | Status changed | semaglutide | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Not yet recruiting → Recruiting | P2 |
| 2026-10-02 | Results date moved | tirzepatide | GLP-1s to Enhance Lasting Optimal Weight | 2026-10-30 → 2027-10-30 12 mo later | P4 |
| 2026-10-02 | New trial registered | semaglutide | SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Not yet recruiting, n=350 | P3 |
| 2026-10-02 | Status changed | orforglipron | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Recruiting → Active, not recruiting | P3 |
| 2026-10-01 | Results date moved | semaglutide | A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes | 2026-11-27 → 2028-02-05 15 mo later | P2 |
| 2026-10-01 | Results date moved | semaglutide | DUTCH Weight Control in Atrial Fibrillation Study | 2026-05-01 → 2027-04-10 11 mo later | P4 |
| 2026-10-01 | Enrollment changed | tirzepatide | Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial | 430 → 726 participants | P2/P3 |
| 2026-10-01 | Results date moved | semaglutide | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) | 2026-09-30 → 2026-09-28 | P2 |
| 2026-10-01 | Enrollment changed | semaglutide | A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes | 240 → 330 participants | P2 |
| 2026-10-01 | Status changed | semaglutide | DUTCH Weight Control in Atrial Fibrillation Study | Recruiting → Active, not recruiting | P4 |
| 2026-10-01 | Status changed | semaglutide | Semaglutide 2.4mg for Low Responders After Bariatric Surgery | Not yet recruiting → Unknown | P4 |
| 2026-09-30 | New trial registered | survodutide | ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease | Not yet recruiting, n=600 | P3 |
| 2026-09-30 | New trial registered | survodutide | SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight | Not yet recruiting, n=600 | P3 |
| 2026-09-30 | Status changed | semaglutide | Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? | Active, not recruiting → Unknown | P4 |
| 2026-09-30 | New trial registered | semaglutide | Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | Active, not recruiting, n=150 | P4 |
| 2026-09-30 | Status changed | semaglutide | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Not yet recruiting → Recruiting | P3 |
| 2026-09-29 | New trial registered | semaglutide | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Not yet recruiting, n=660 | P3 |
| 2026-09-29 | New trial registered | semaglutide | SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Not yet recruiting, n=50 | P3 |
| 2026-09-29 | Enrollment changed | semaglutide | Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | 176 → 175 participants | P2 |
| 2026-09-29 | Status changed | semaglutide | A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity | Recruiting → Active, not recruiting | P2 |
| 2026-09-29 | New trial registered | tirzepatide | Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial | Not yet recruiting, n=256 | P2/P3 |
| 2026-09-29 | Status changed | tirzepatide | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Active, not recruiting → Completed | P2 |
| 2026-09-29 | Status changed | maridebart cafraglutide | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Recruiting → Active, not recruiting | P3 |
| 2026-09-29 | Results date moved | maridebart cafraglutide | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-09-29 → 2027-08-30 1 mo earlier | P3 |
| 2026-09-28 | New trial registered | petrelintide | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease | Not yet recruiting, n=2,500 | P3 |
| 2026-09-28 | New trial registered | petrelintide | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Not yet recruiting, n=600 | P3 |
| 2026-09-28 | New trial registered | petrelintide | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Not yet recruiting, n=3,900 | P3 |
| 2026-09-28 | Status changed | semaglutide | A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Not yet recruiting → Recruiting | P3 |
| 2026-09-28 | Results date moved | semaglutide | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | 2026-08 → 2026-08-27 | P3 |
| 2026-09-28 | Status changed | tirzepatide | Tirzepatide for Obesity and Meth Use DisorderNCT06745128 · University of Texas Southwestern Medical Center | Active, not recruiting → Completed | P2 |
| 2026-09-28 | Results date moved | tirzepatide | Tirzepatide for Obesity and Meth Use DisorderNCT06745128 · University of Texas Southwestern Medical Center | 2026-03-31 → 2026-02-12 1 mo earlier | P2 |
| 2026-09-28 | Enrollment changed | tirzepatide | Tirzepatide for Obesity and Meth Use DisorderNCT06745128 · University of Texas Southwestern Medical Center | 45 → 35 participants | P2 |
| 2026-09-28 | Results date moved | tirzepatide | GLP-1s to Enhance Lasting Optimal Weight | 2026-09-30 → 2026-10-30 1 mo later | P4 |
| 2026-09-28 | New trial registered | mazdutide | A Study of HRS-4729 Injection in Participants With Type 2 Diabetes | Not yet recruiting, n=240 | P2 |
| 2026-09-28 | Status changed | maridebart cafraglutide | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | Recruiting → Active, not recruiting | P2 |
| 2026-09-28 | Results date moved | maridebart cafraglutide | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | 2027-09-29 → 2027-08-25 1 mo earlier | P2 |
| 2026-09-28 | Removed from registry | semaglutide | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss NCT07837973 · Alveus Therapeutics, Inc. | Last seen as Recruiting | P2 |
| 2026-09-25 | Results date moved | semaglutide | A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsNCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07 → 2026-03-07 4 mo earlier | P3 |
| 2026-09-25 | Results date moved | semaglutide | Effect of Itopride on Semaglutide Gastroparesis | 2026-04 → 2026-07-30 3 mo later | P4 |
| 2026-09-25 | Status changed | semaglutide | A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsNCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting → Completed | P3 |
| 2026-09-25 | Status changed | semaglutide | Effect of Itopride on Semaglutide Gastroparesis | Recruiting → Completed | P4 |
| 2026-09-24 | New trial registered | semaglutide | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss NCT07837973 · Alveus Therapeutics, Inc. | Recruiting, n=220 | P2 |
| 2026-09-23 | Results date moved | mazdutide | Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | 2028-08-31 → 2029-02-28 6 mo later | P4 |
| 2026-09-23 | New trial registered | semaglutide | A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.NCT07836140 · Second Affiliated Hospital of Soochow University | Completed, n=60 | P2 |
| 2026-09-23 | Status changed | tirzepatide | Tirzepatide for Treatment of CCCA | Not yet recruiting → Recruiting | P2 |
| 2026-09-23 | Status changed | mazdutide | Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | Not yet recruiting → Recruiting | P4 |
| 2026-09-23 | field_changed | mazdutide | Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | | P4 |
| 2026-09-23 | New trial registered | ecnoglutide | A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents | Not yet recruiting, n=192 | P3 |
| 2026-09-22 | New trial registered | semaglutide | Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes | Completed, n=150 | P3 |
| 2026-09-22 | Status changed | orforglipron | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Not yet recruiting → Recruiting | P3 |
| 2026-09-22 | Status changed | mazdutide | A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Recruiting → Active, not recruiting | P2 |
| 2026-09-21 | Results date moved | semaglutide | Semaglutide for Post-Smoking Cessation Weight ManagementNCT06173778 · The University of Texas Health Science Center, Houston | 2026-07-01 → 2028-05-25 22 mo later | P2 |
| 2026-09-21 | Results date moved | semaglutide | The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | 2026-01-15 → 2027-01-15 12 mo later | P2 |
| 2026-09-21 | Results date moved | tirzepatide | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | 2027-11 → 2027-08 3 mo earlier | P4 |
| 2026-09-21 | New trial registered | semaglutide | Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Not yet recruiting, n=60 | P4 |
| 2026-09-21 | Status changed | tirzepatide | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Recruiting → Active, not recruiting | P4 |
| 2026-09-21 | Results date moved | liraglutide | A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | 2026-08-28 → 2026-08-31 | P2 |
| 2026-09-21 | Status changed | efinopegdutide | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Active, not recruiting → Completed | P2 |
| 2026-09-21 | Results date moved | efinopegdutide | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | 2026-08-06 → 2026-08-03 | P2 |
| 2026-09-21 | Enrollment changed | efinopegdutide | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | 80 → 85 participants | P2 |
| 2026-09-21 | New trial registered | olatorepatide | Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity | Not yet recruiting, n=300 | P2 |
| 2026-09-18 | New trial registered | tirzepatide | Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Not yet recruiting, n=70 | P3 |
| 2026-09-18 | Status changed | maridebart cafraglutide | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Recruiting → Active, not recruiting | P3 |
| 2026-09-18 | Results date moved | maridebart cafraglutide | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-09-29 → 2027-09-03 | P3 |
| 2026-09-17 | Status changed | semaglutide | Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Active, not recruiting → Completed | P2 |
| 2026-09-17 | Results date moved | semaglutide | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) | 2026-09 → 2026-09-30 | P2 |
| 2026-09-17 | Status changed | tirzepatide | Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Not yet recruiting → Recruiting | P4 |
| 2026-09-17 | New trial registered | tirzepatide | Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderNCT07825857 · University of Texas Southwestern Medical Center | Not yet recruiting, n=228 | P2 |
| 2026-09-17 | New trial registered | mazdutide | Mazdutide for Weight Management and Gout in Adults With Obesity | Not yet recruiting, n=30 | P4 |
| 2026-09-16 | Results date moved lead | semaglutide | Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | 2027-11-30 → 2029-06-30 19 mo later | P2/P3 |
| 2026-09-16 | Enrollment changed | semaglutide | Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | 74 → 37 participants | P2/P3 |
| 2026-09-16 | Status changed | semaglutide | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Recruiting → Active, not recruiting | P2 |
| 2026-09-16 | Results date moved | semaglutide | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | 2027-07-12 → 2027-06-14 1 mo earlier | P2 |
| 2026-09-16 | Enrollment changed | semaglutide | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | 230 → 233 participants | P2 |
| 2026-09-15 | Results date moved lead | semaglutide | Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | 2029-06 → 2030-03 9 mo later | P3 |
| 2026-09-15 | New trial registered | semaglutide | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial | Completed, n=159 | P3 |
| 2026-09-15 | New trial registered | semaglutide | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial CancerNCT07820358 · The Methodist Hospital Research Institute | Not yet recruiting, n=48 | P2 |
| 2026-09-14 | Results date moved | semaglutide | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | 2026-12 → 2027-05 5 mo later | P2 |
| 2026-09-14 | Results date moved | semaglutide | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | 2031-09-30 → 2028-10-31 35 mo earlier | P2 |
| 2026-09-14 | Results date moved | semaglutide | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | 2026-07-31 → 2027-10-31 15 mo later | P4 |
| 2026-09-14 | Results date moved | orforglipron | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | 2026-11 → 2026-07-21 4 mo earlier | P3 |
| 2026-09-14 | Status changed | semaglutide | Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)NCT07653477 · The United Bio-Technology (Hengqin) Co., Ltd. | Not yet recruiting → Recruiting | P3 |
| 2026-09-14 | New trial registered | semaglutide | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Not yet recruiting, n=210 | P3 |
| 2026-09-14 | Enrollment changed | semaglutide | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | 240 → 200 participants | P2 |
| 2026-09-14 | Enrollment changed | semaglutide | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | 826 → 100 participants | P2 |
| 2026-09-14 | field_changed | semaglutide | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | | P2 |
| 2026-09-14 | New trial registered | semaglutide | Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide | Completed, n=41 | P2 |
| 2026-09-14 | Status changed | semaglutide | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | Recruiting → Active, not recruiting | P4 |
| 2026-09-14 | New trial registered | tirzepatide | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Not yet recruiting, n=150 | P3 |
| 2026-09-14 | Status changed | orforglipron | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Active, not recruiting → Completed | P3 |
| 2026-09-14 | Enrollment changed | orforglipron | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | 600 → 712 participants | P3 |
| 2026-09-11 | Status changed | tirzepatide | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Active, not recruiting → Completed | P2 |
| 2026-09-11 | Results date moved | tirzepatide | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | 2026-09 → 2026-07-06 2 mo earlier | P2 |
| 2026-09-11 | Enrollment changed | tirzepatide | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | 140 → 134 participants | P2 |
| 2026-09-10 | New trial registered | semaglutide | · NOVO | | |
| 2026-09-10 | Results date moved | semaglutide | Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | 2026-07 → 2027-01 6 mo later | P2 |
| 2026-09-10 | Status changed | semaglutide | Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Recruiting → Active, not recruiting | P2 |
| 2026-09-10 | Status changed | semaglutide | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Active, not recruiting → Completed | P2 |
| 2026-09-10 | Results date moved | semaglutide | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | 2026-08-21 → 2026-06-26 2 mo earlier | P2 |
| 2026-09-10 | New trial registered | semaglutide | A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) | Not yet recruiting, n=210 | P2 |
| 2026-09-09 | Status changed | semaglutide | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Not yet recruiting → Recruiting | P3 |
| 2026-09-09 | Results date moved | tirzepatide | A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | 2026-08-22 → 2026-09-03 1 mo later | P2 |
| 2026-09-09 | Status changed | petrelintide | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Active, not recruiting → Completed | P2 |
| 2026-09-08 | Results date moved | semaglutide | Semaglutide for Smoking Cessation in Patients With DiabetesNCT07059377 · Ottawa Heart Institute Research Corporation | 2026-07 → 2026-12 5 mo later | P3 |
| 2026-09-04 | Status changed | semaglutide | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia | Active, not recruiting → Completed | P4 |
| 2026-09-04 | Enrollment changed | semaglutide | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia | 504 → 92 participants | P4 |
| 2026-09-04 | Status changed | semaglutide | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Recruiting → Active, not recruiting | P2 |
| 2026-09-04 | Enrollment changed | semaglutide | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | 200 → 239 participants | P2 |
| 2026-09-04 | Status changed | semaglutide | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Not yet recruiting → Recruiting | P3 |
| 2026-09-03 | field_changed lead | tirzepatide | · | | |
| 2026-09-03 | New trial registered | tirzepatide | · ELI LILLY AND CO | | |
| 2026-09-03 | New trial registered | tirzepatide | · ELI LILLY AND CO | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | Enrollment changed | semaglutide | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | 125 → 140 participants | P4 |
| 2026-09-03 | New trial registered | semaglutide | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Recruiting, n=240 | P2 |
| 2026-09-02 | Results date moved | semaglutide | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | 2027-09-20 → 2026-01-20 20 mo earlier | P2 |
| 2026-09-02 | Status changed | semaglutide | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | Recruiting → Completed | P2 |
| 2026-09-02 | Enrollment changed | semaglutide | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | 105 → 114 participants | P2 |
| 2026-09-02 | Status changed | semaglutide | Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction | Not yet recruiting → Unknown | P4 |
| 2026-09-01 | New trial registered | semaglutide | Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes | Not yet recruiting, n=226 | P2/P3 |
| 2026-09-01 | Results date moved | semaglutide | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | 2026-05-06 → 2026-06-16 1 mo later | P2 |
| 2026-09-01 | New trial registered | tirzepatide | A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | Not yet recruiting, n=240 | P2 |
| 2026-08-31 | New trial registered | orforglipron | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Not yet recruiting, n=2,001 | P3 |
| 2026-08-31 | New trial registered | pemvidutide | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | Recruiting, n=1,800 | P3 |
| 2026-08-31 | Status changed | semaglutide | Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial | Not yet recruiting → Recruiting | P3 |
| 2026-08-31 | Status changed | liraglutide | A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Not yet recruiting → Unknown | P3 |
| 2026-08-31 | Status changed | mazdutide | A Study of IBI362 9 mg in Chinese Adults With Obesity | Active, not recruiting → Unknown | P3 |
| 2026-08-31 | Status changed | ecnoglutide | A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) | Not yet recruiting → Recruiting | P3 |
| 2026-08-28 | field_changed | liraglutide | · | | |
| 2026-08-28 | Results date moved | semaglutide | GLP-1R Agonist Treatment for Opioid Use Disorder | 2027-04 → 2027-04-30 | P2 |
| 2026-08-28 | Status changed | tirzepatide | Tirzepatide in Idiopathic Intracranial Hypertension Trial | Not yet recruiting → Recruiting | P4 |
| 2026-08-28 | Results date moved | mazdutide | Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · China National Center for Cardiovascular Diseases | 2027-10-31 → 2027-12-31 2 mo later | P4 |
| 2026-08-27 | New trial registered lead | tirzepatide | · ELI LILLY AND CO | | |
| 2026-08-27 | New trial registered lead | tirzepatide | · ELI LILLY AND CO | | |
| 2026-08-27 | New trial registered | semaglutide | · NOVO | | |
| 2026-08-27 | Status changed | tirzepatide | GLP-1R Actions on Muscle and the Skeleton | Active, not recruiting → Recruiting | P4 |
| 2026-08-27 | New trial registered | orforglipron | A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems | Not yet recruiting, n=192 | P3 |
| 2026-08-26 | New trial registered lead | tirzepatide | · ELI LILLY AND CO | | |
| 2026-08-26 | Results date moved | tirzepatide | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | 2028-12-31 → 2029-10-31 10 mo later | P2 |
| 2026-08-25 | New trial registered | semaglutide | A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or ObesityNCT07783854 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting, n=72 | P4 |
| 2026-08-24 | Status changed | tirzepatide | Incretin Therapies in Obesity-related HFpEF | Not yet recruiting → Recruiting | P4 |
| 2026-08-24 | New trial registered | mazdutide | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Not yet recruiting, n=128 | P2 |
| 2026-08-24 | Status changed | maridebart cafraglutide | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Not yet recruiting → Recruiting | P3 |
| 2026-08-21 | New trial registered | lixisenatide | iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) | Completed, n=582 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes | Completed, n=736 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM | Completed, n=1,170 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) | Completed, n=6,068 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs | Completed, n=513 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Completed, n=680 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients | Completed, n=894 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) | Completed, n=878 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea | Completed, n=859 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Completed, n=521 | P3 |
| 2026-08-21 | New trial registered | aleniglipron | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Recruiting, n=1,100 | P3 |
| 2026-08-21 | New trial registered | aleniglipron | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)NCT07654361 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Recruiting, n=3,600 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes | Completed, n=685 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine | Completed, n=586 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. | Completed, n=507 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes | Completed, n=779 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus | Completed, n=814 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes | Completed, n=1,049 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes | Completed, n=8 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | Not yet recruiting, n=324 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes | Completed, n=294 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin | Completed, n=426 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients | Completed, n=350 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Completed, n=321 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents | Terminated, n=241 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes | Enrolling by invitation, n=100 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric EmptyingNCT01910194 · Profil Institut für Stoffwechselforschung GmbH | Completed, n=39 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) | Completed, n=265 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | The Effect of Lixisenatide on the Effect of Pituitary Hormones | Unknown, n=10 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin | Completed, n=496 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease | Completed, n=156 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) | Completed, n=69 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Completed, n=119 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog | Terminated, n=2 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes | Completed, n=361 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan | Completed, n=184 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone | Completed, n=484 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Study on Lixisenatide and Counterregulation to Hypoglycemia | Completed, n=18 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy | Completed, n=361 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effects of Insulin Glargine and Lixisenatide on the Brain | Terminated, n=1 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) | Completed, n=247 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin | Completed, n=391 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years | Completed, n=319 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine | Completed, n=446 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus | Completed, n=124 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | iGlarLixi CGM Study in Chinese T2D Individuals After OADs | Recruiting, n=678 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus | Completed, n=542 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients | Completed, n=323 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents | Recruiting, n=1,316 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) | Completed, n=311 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin | Completed, n=10 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients | Terminated, n=2 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Completed, n=484 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine | Completed, n=136 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi | Completed, n=161 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus | Completed, n=105 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of LIXIsenatide on the Renal System | Completed, n=40 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin | Completed, n=447 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin | Completed, n=451 | P3 |
| 2026-08-21 | New trial registered | aleniglipron | Aleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Active, not recruiting, n=58 | P2 |
| 2026-08-21 | New trial registered | aleniglipron | Aleniglipron Phase 2 Body Composition StudyNCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Active, not recruiting, n=71 | P2 |
| 2026-08-21 | New trial registered | aleniglipron | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Completed, n=230 | P2 |
| 2026-08-21 | New trial registered | aleniglipron | A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06703021 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Completed, n=85 | P2 |
| 2026-08-21 | New trial registered | olatorepatide | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes | Recruiting, n=360 | P2 |
| 2026-08-21 | New trial registered | olatorepatide | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Active, not recruiting, n=120 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus | Completed, n=67 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Dose Ranging Study of Albiglutide in Japanese Subjects | Completed, n=215 | P2 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus | Withdrawn | P3 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | Completed, n=309 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus | Completed, n=9,463 | P4 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus | Completed, n=374 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes | Completed, n=44 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy of Albiglutide in Type 2 Diabetes | Completed, n=310 | P3 |
| 2026-08-21 | New trial registered | albiglutide | In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus | Completed, n=60 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects | Terminated, n=8 | P4 |
| 2026-08-21 | New trial registered | albiglutide | Pharmacokinetics/Pharmacodynamics of Albiglutide | Completed, n=283 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus | Completed, n=308 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus | Withdrawn | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects | Completed, n=20 | P4 |